| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.0077 | 0.8 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | -0.0086 | 0.8 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.8 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.04 | 0.8 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.8 |
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | -0.0073 | 0.8 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.0084 | 0.8 |